The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases

Charlotte Delrue1, Reinhart Speeckaert2, Joris R Delanghe3

  • 1Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium.

Insights

Advanced glycation end products (AGEs) impact cell function and are linked to rheumatic diseases. Soluble RAGE (sRAGE) acts as a decoy, and its levels may indicate disease progression and cardiovascular risk.

Area of Science:

  • Biochemistry
  • Immunology
  • Rheumatology

Background:

  • Advanced glycation end products (AGEs) form from sugar-protein interactions, altering protein structure and activating the receptor for advanced glycation end products (RAGE).
  • RAGE activation contributes to cellular and tissue dysfunction, and is implicated in chronic inflammatory autoimmune disorders like rheumatoid arthritis, lupus, and Sjögren's syndrome.
  • The soluble form of RAGE (sRAGE) acts as a decoy receptor, inhibiting RAGE-mediated pro-inflammatory signaling.

Purpose of the Study:

  • To review the roles of AGEs, sRAGE, and RAGE polymorphisms in rheumatic diseases.
  • To explore the connection between AGE overproduction, atherosclerosis, and disease pathogenesis.
  • To examine the clinical significance of sRAGE levels and RAGE polymorphisms in rheumatic conditions.

Main Methods:

  • Literature review of studies investigating AGEs, RAGE, and sRAGE in rheumatic diseases.
  • Analysis of the biochemical mechanisms of AGEs and RAGE signaling.
  • Examination of the association between RAGE polymorphisms and disease susceptibility.

Main Results:

  • AGE overproduction is linked to rheumatic disease pathogenesis and accelerated atherosclerosis.
  • Low serum sRAGE concentrations correlate with increased cardiovascular risk and poorer prognosis.
  • Certain RAGE polymorphisms may be associated with heightened susceptibility to rheumatic diseases.

Conclusions:

  • AGEs and RAGE play significant roles in the development and progression of rheumatic diseases.
  • sRAGE levels serve as a potential biomarker for disease activity, cardiovascular risk, and prognosis.
  • RAGE polymorphisms represent a potential genetic factor influencing disease susceptibility in rheumatic conditions.

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
27
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
13.8K
Proteoglycans01:05

Proteoglycans

Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
4.0K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
43
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
24